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Abstract 
Background: Despite improved clinical outcomes seen following antiretroviral therapy (ART), resting CD4+ T cells 
continue to harbor latent human immunodeficiency virus type one (HIV-1). However, such cells are not likely the 
solitary viral reservoir and as such defining where and how others harbor virus is imperative for eradication measures. 
To such ends, we used HIV-1ADA-infected NOD.Cg-Prkdc
scid Il2rgtm1Wjl/SzJ mice reconstituted with a human immune 
system to explore two long-acting ART regimens investigating their abilities to affect viral cell infection and latency. 
At 6 weeks of infection animals were divided into four groups. One received long-acting (LA) cabotegravir (CAB) and 
rilpivirine (RVP) (2ART), a second received LA CAB, lamivudine, abacavir and RVP (4ART), a third were left untreated 
and a fourth served as an uninfected control. After 4 weeks of LA ART treatment, blood, spleen and bone marrow 
(BM) cells were collected then phenotypically characterized. CD4+ T cell subsets, macrophages and hematopoietic 
progenitor cells were analyzed for HIV-1 nucleic acids by droplet digital PCR.
Results: Plasma viral loads were reduced by two log10 or to undetectable levels in the 2 and 4ART regimens, respec-
tively. Numbers and distributions of CD4+ memory and regulatory T cells, macrophages and hematopoietic progeni-
tor cells were significantly altered by HIV-1 infection and by both ART regimens. ART reduced viral DNA and RNA in all 
cell and tissue compartments. While memory cells were the dominant T cell reservoir, integrated HIV-1 DNA was also 
detected in the BM and spleen macrophages in both regimen-treated mice.
Conclusion: Despite vigorous ART regimens, HIV-1 DNA and RNA were easily detected in mature macrophages  
supporting their potential role as an infectious viral reservoir.
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Background
Combination antiretroviral therapy (ART) reduces 
plasma human immunodeficiency virus (HIV) to unde-
tectable levels in the infected human host [1, 2]. None-
theless, ART-induced suppressed viremia rapidly 
re-occurs after treatment interruption [3–5]. ART fail-
ures to “cure” viral infection lead to the establishment of 
a stable latent viral reservoir [6–9]. In attempts to define 
this reservoir studies were initiated for both HIV and 
simian immunodeficiency virus (SIV) infections. Viral 
nucleic acids were detected in CD4+ T cells from blood, 
lymph node and gut associated lymphoid tissues (GALT) 
during ART [10–24]. Target cells for viral latency were 
within central memory (TCM) and transitional memory 
(TTM) CD4+ T cell pools [25–30]. Infected TCM cells first 
emerged during cell reconstitution within CD4+ T lym-
phocyte compartments after ART intervention [31–35] 
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and were maintained during plasma virus reductions and 
immune reconstitution [34, 35].
TTM cells harbor significant amounts of proviral DNA 
and release progeny virus during the course of infec-
tion. These infected cells are most prominent when 
CD4+ T cell numbers are depleted during advanced dis-
ease [36–39]. While broad research in this area has been 
completed for more than a decade including linkages to 
cytokine dynamics and other parts of immune microen-
vironment little is known about the tempo of cell trans-
formation and viral replication patterns. Defining such 
virus-host cell interactions is critical for selecting treat-
ment interventions that interfere with the self-renewal 
and persistence of latently infected cells, which can ulti-
mately lead to viral eradication.
To study disease patterns seen after viral infection 
and immune suppression, we constructed NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice reconstituted with 
CD34+ human stem cells (HSC) [10–13, 40–43]. The 
HIV-1 infected humanized NSG mice can mimic criti-
cal features of human disease and are suitable to explore 
antiretroviral and adjunctive therapies [10–13, 40]. Note-
worthy limitations include the life span of the human 
grafts and the human cell recovery rates.
In the present report, humanized NSG mice were 
infected with HIV-1ADA then treated with two long-
acting (LA) slow-release antiretroviral drug (ARV) 
regimens. LA ARVs were employed to optimize drug 
pharmacokinetic profiles [44–46]. One regimen con-
tained LA cabotegravir (CAB) and rilpivirine (RVP) 
and prodrug nanoformulations of both lamivudine and 
abacavir (NM3TC and NMABC) [45, 46]. Another regi-
men used CAB and RVP. For simplicity in this report, 
the regimens are designated as 4ART and 2ART, 
respectively. The mice were infected for 6  weeks fol-
lowed by ART administration for a month. At the 
study conclusion, animals were euthanized, immune 
cells isolated and viral nucleic acids examined by PCR 
amplification.
CD4+ T cells were recovered in blood, spleen and 
bone marrow (BM) of all ART-treated mice. How-
ever, HIV-1 infection affected numbers of memory and 
regulatory CD4+ T cells and monocyte–macrophages 
with limitations made on broad numerical cell com-
parisons. However, all cell types were readily restored 
by the ART regimens. Viral DNA and RNA levels were 
reduced by ART intervention. Interestingly, infected 
monocyte–macrophage populations persisted in spleen 
and BM tissues and were readily detected even consider-
ing rates of human cell reconstitutions. These findings, 
taken together, provide a model for future investigations 




New-born NSG mice were transplanted with human 
CD34+ stem cells obtained from human umbilical cord 
blood as previously described [13, 47]. After 15  weeks 
of reconstitution by human CD34+ HSC, mice were 
selected for further study based on their repopula-
tion with human CD45+ cell numbers as monitored 
in peripheral blood. These animals were then infected 
with the macrophage tropic virus HIV-1ADA by intra-
peritoneal injection at 104 tissue culture infective dose 
50 (TCID50)/mouse. Virus was prepared by infecting 
human monocyte-derived macrophages, then tittering 
the recovered virions as previously described [48]. After 
6 weeks of infection, animals were randomly assigned to 
three groups; one group was treated with the 2ART regi-
men (HIV+2ART), one group was treated with the 4ART 
regimen (HIV+4ART), and one infected group remained 
untreated (HIV+). A fourth group of humanized NSG 
mice were uninfected and untreated, and served as 
negative controls (HIV−). After 4  weeks of treatment 
(10 weeks total following infection), animals were euth-
anized for immune cell phenotyping, flow cytometric 
sorting and virus detection in plasma and tissue. The 
10  weeks total experimental time after infection facili-
tated the analysis and experimental studies and reduced 
the risk for great reduction of human cells in the trans-
planted animals.
Quantification of plasma HIV‑1 viral load (PVL)
Peripheral blood samples were collected into ethylen-
ediaminetetraacetic acid (EDTA)-coated tubes from the 
facial vein and plasma was separated from blood cells 
by low speed centrifugation. The quantification of PVL 
of the virus-infected humanized NSG mice collected 
at 6 and 10  weeks post-infection was performed using 
the Taqman Analyzer according to the manufacturer’s 
instructions (Roche Diagnostics, Indianapolis, IN, USA).
Antiretroviral drug (ARV) treatments
CAB, lamivudine (3TC) and abacavir (ABC) were 
obtained as generous gifts from GlaxoSmithKline (GSK) 
(Brentford, England, UK). CAB LA was prepared for 
use as a nanoformulation. 3TC and ABC were manufac-
tured as prodrugs and encased in LA formulations by 
high-pressure homogenization [44–46]. RVP was pur-
chased from Leap Labchem Co (HangZhou, China) and 
encapsulated into poloxamer 407 (Sigma Aldrich, St. 
Louis, MO, USA) nanosuspension [49]. Physicochemi-
cal parameters of each of the formulations including 
particle size, charge, polydispersity, shape and formu-
lation stability were determined [44–46]. CAB LA and 
RPV LA were injected intramuscularly as a single dose 
Page 3 of 13Araínga et al. Retrovirology  (2017) 14:17 
at concentrations of 45  mg/Kg. NM3TC and NMABC 
were injected intramuscularly every week at concen-
trations of 40 mg/Kg. Drug treatment ended at 4 weeks 
when all animals were euthanized (Additional file 1: Fig-
ure S1). Drug concentrations in plasma, liver, lung, gut 
and or brain were quantified by ultra-performance liquid 
chromatography-tandem mass spectrometry during the 
course or end of treatment as previously described [10, 
44–46]. Plasma values for CAB, RPV, 3TC and ABC were 
at or around the inhibitory concentration50 for each of 
the study drugs at the study end (data not shown).
Peripheral blood and tissue collections
At study end, animals from the HIV-1, HIV-1 2ART or 
4ART regimens and uninfected controls had their blood 
and tissue subjected to cell phenotype analyses. Blood 
samples were collected into EDTA-coated tubes by cardi-
ocentesis at the time of euthanasia. Spleen and BM were 
collected in Roswell Park Memorial Institute (RPMI) 
media supplemented with fetal bovine sera (Thermo 
Fisher, Waltham, MA, USA). Recovered cells were pro-
cessed to single cell suspensions for cell phenotype, sort-
ing and viral quantification. Single cells from spleen and 
BM of HIV-1 infected NSG mice were separated into 
four aliquots for cell phenotyping, sorting, drug analysis 
and viral quantification. Tissues recovered included lung, 
gut, lymph nodes and brain were stored after recovery at 
−80 °C for subsequent viral quantification.
Flow cytometry
For cell phenotyping, 100 μL of 105 cell suspensions were 
acquired from whole blood, spleen and BM then incu-
bated for 30  min with monoclonal antibodies to iden-
tify T cell subtypes, hematopoietic progenitor cells and 
monocyte–macrophages by flow cytometry [40]. Human 
monoclonal antibodies against CD45, CD3, CD4, CD8, 
CD45RA, CD45RO, CD95 and CCR7 identified frequen-
cies of immunocyte populations. Memory CD4+ T cells 
were subtyped as stem cell memory (TSCM), central mem-
ory (TCM) and effector memory (TEM) with the expres-
sion of CD45RA+/CCR7+CD95+, CD45RO+/CCR7+ 
and CD45RO+/CCR7−, respectively, from the CD45+/
CD3+/CD4+ gate. Moreover, CD4+ regulatory T cells 
(TREG) were classified as CD127+lowCD25+, hematopoi-
etic progenitor cells CD34 as lineage-CD34+ cells and 
monocyte–macrophages as CD3−/CD20−/CD8−/HLA-
DR+/CD14++CD16+ cells. Flow cytometric acquisi-
tion and sample analysis was performed on a LSRII flow 
cytometer driven by the FACSDiva software package (BD 
Biosciences, CA, USA). All antibodies were obtained 
from BD Biosciences (San Jose, CA, USA).
Single cell suspensions were prepared from spleen and 
BM for cell sorting. Humanized NSG animal from all 
four groups were analysed from pooled cells and tissues. 
Human CD45+ cells obtained by magnetic beads were 
incubated with antibody panels for 30 min then used for 
flow cytometric sorting to isolate memory and regulatory 
cell populations, macrophages and CD34+ progenitor 
cells. The recovered cell populations included TSCM, TCM, 
TEM, TREG, total CD4+ T cells, monocyte–macrophages 
and hematopoietic progenitor cells. Each population 
were live-cell sorted in a designated BSL2 level biosafety 
cabinet using an Aria cell sorter (BD, Franklin Lakes, 
NJ, USA). During sorting, cell were collected in RPMI 
media, on ice, then pelleted by centrifugation and stored 
at −80  °C. Cell sorting was performed by the UNMC 
Flow Cytometry Core Facility. Analysis of all the acquired 
data was performed using FlowJo Version 10.08 software 
(TreeStar Inc., San Carlos, CA, USA).
Nucleic acid extraction
Total viral nucleic acids extracted from tissue or from 
cells were acquired from the spleen, BM, lung, gut, lymph 
node, brain or from sorted cells using a Qiagen Kit (Qia-
gen, Hilden, Germany) according to the manufacturer’s 
instructions. Aliquots of eluted samples were used for 
PCR tests or frozen at −80  °C for later use. Total cell 
DNA and RNA obtained from the HIV-1 infected cell 
line ACH2 served as a positive control [40]. Human cells 
obtained from uninfected control animals were used as 
negative controls. Cell-associated HIV-1 RNA and DNA 
were quantified by droplet digital PCR (ddPCR).
ddPCR for detection of HIV‑1 nucleic acids
ddPCR test based on the water–oil emulsion drop-
let technology, was used for viral detection using spe-
cific primers and a TaqMan probe. For quantification of 
viral RNA, eluted cellular RNA was used as template for 
reverse transcription to synthesize first-strand cDNA 
using the iScript™ Reverse Transcription Supermix for 
RT-qPCR (Bio-Rad Laboratories, Hercules, CA, USA). 
The acquired cDNA was divided into two portions, the 
first for the detection of unspliced and the second for 
multiply-spliced viral RNA (usRNA and msRNA). The 
ddPCR assay for msRNA was performed with a primer 
pairs that amplified msRNA from the tat and rev genes 
[40, 50]. For usRNA tests, primers and fluorescent probes 
for amplification employed the HIV-1 gag gene region 
[40]. The ddPCR assay was run using the ddPCR™ Super-
mix for Probes reagents and in the QX200™ Droplet 
Digital™ PCR system (Bio-Rad Laboratories, Hercules, 
CA, USA). For the quantification of total and integrated 
HIV-1 DNA, the eluted cellular DNA was directly sub-
jected to two rounds of PCR amplification. We modified 
a previously published protocol [50] for the amplifica-
tion of total viral DNA (vDNA) targeting the HIV-1 gag 
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gene. For the detection of integrated DNA (inDNA) we 
used an adapted alu-PCR assay [51] with modifications 
[40, 50]. The first round of the PCR was performed on a 
conventional PCR machine in 25 μL of PCR master mix, 
using the iTaq™ DNA Polymerase reagents (Bio-Rad Lab-
oratories, Hercules, CA, USA) with specific primers [40]. 
The product of the first PCR was subsequently used as a 
template for the ddPCR amplification performed on the 
QX200™ Droplet Digital™ PCR system (Bio-Rad Labora-
tories, Hercules, CA, USA), using the ddPCR™ Supermix 
for Probes reagents and following the thermal cycling 
conditions for TaqMan detection chemistry as instructed 
by the manufacturer. Data acquisition and analysis were 
done using QX200 droplet reader and QuantaSoft™ soft-
ware (Bio-Rad Laboratories, Hercules, CA, USA).
Statistics
Univariate or bivariate homoscedastic data were evalu-
ated by one- or two-way ANOVA, respectively, followed 
by appropriate post hoc tests. Nonparametric methods 
were utilized for non-normally distributed or heterosce-
dastic data. Data analyses were performed using Prism 
(v6, GraphPad Software, Inc., La Jolla, CA) and Statistica 
(v9, StatSoft, Inc., Tulsa, OK), and are presented within 
the text and figures as mean ± SEM.
Results
Viral replication in HIV‑1 infected and ART‑treated 
humanized mice
We examined two LA ARV regimens for their effects on 
infectious reservoirs within HIV-1 infected humanized 
mice. Four groups of humanized NSG mice were evalu-
ated (Additional file 1: Figure S1). Virus was first assayed 
in plasma at 6 then at 10 weeks following viral infection 
(pre and post-treatment), respectively. VL in plasma 
from HIV-1 infected mice had on average 106 copies/
mL of virus at 6–10 weeks of infection. The viral copies/
mL after the 2ART regimen was reduced to 104 copies/
mL and to undetectable levels in the 4ART group with 
one exception where one animal showed 103 copies/mL 
(Fig. 1). The results showed that four ARVs could reduce 
VL at or below the limit of detection in plasma samples 
of infected humanized mice. Second, we tested cellular 
responses, altered as a consequence of HIV-1 infection 
and ART. The percentages of CD4+ T cells were evalu-
ated 10  weeks after viral infection at study termination. 
Cell quantitation was performed 10 weeks after infection 
in blood, spleen and BM tissues from each of the mouse 
groups. As expected, we observed depletion of CD4+ T 
cells in blood, spleen and BM in the HIV-1 infected mice 
versus the uninfected animal group (Fig. 2a). Differences 
between the two animal groups were profound. CD4+ T 
cell percentages (mean ± SEM) were 18.1% ± 3.5 versus 
37.0% ± 11.5 (in blood); 15.7% ± 3.7 versus 57.5% ± 4.9 
(in spleen); and 33.9% ± 6.1 versus 55.9% ± 4.8 (in BM). 
The value differences were similar to those previously 
reported [40].
CD4+ T cell subset frequencies
We recently showed changes in cellular subsets follow-
ing HIV-1 infection [40]. Further investigation of these 
cells was initiated after ART and illustrated (Fig.  2a–c). 
CD4+ T cells recovered from spleen in the 2ART and 
4ART regimens were restored to uninfected control lev-
els (Fig.  2a). Frequencies of TSCM, TCM, TEM, and TREG 
acquired from spleen and BM were evaluated follow-
ing viral infection and ART. Interestingly, during ART, 
profound changes were seen in spleen and BM cells. In 
uninfected controls the frequencies of TEM and TREG 
were 22.4% ± 5.7 and 10.0% ± 2.7, respectively. During 
viral infection, these cell frequencies were reduced by 
3- and 5-fold, 7.2%  ±  1.7 and 1.8%  ±  0.4, respectively, 
but recovered during ART. Frequencies of TEM in 2ART 
and 4ART groups were 15.5%  ±  2.2 and 16.8%  ±  0.7, 
respectively, while TREG frequencies were 7.7% ± 1.8 and 
4.5% ± 0.5 cells, respectively. In BM, TEM were reduced 
to half during infection, but recovered to uninfected lev-
els with both ART regimens. For TREG, the frequencies 
were one-third of the uninfected controls, but reached 
uninfected control values with both antiretroviral regi-
mens. No significant changes for TSCM and TCM fre-
quencies were detected in spleen. However, in BM, TSCM 
frequency increased after viral infection to 7.3%  ±  1.9 
Fig. 1 PVL quantification in the plasma of HIV-1 infected and ART 
treated humanized mice. Humanized NSG mice were infected with 
HIV-1ADA and after 6 weeks of infection, VL was determined. Then, 
infected animals were distributed into three groups: untreated con-
trol, treated with 2ART or 4ART regimens. Plasma VL was measured 
after 4 weeks of treatment (10 weeks of HIV-1 infection). The figures 
represent viral copies/mL detected in plasma, using the COBAS 
Amplilink detection system. Two-way ANOVA for means (bar) of log10 
copies/mL for 4–9 mice/group showed an effect of treatment by time 
(P = 0.00003). P values from pairwise comparison with Tukey’s HSD 
post hoc test are shown above each pre- and post-treatment pair 
groups
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versus 2.5%  ±  0.9 in uninfected animals. With 2ART, 
TSCM numbers were reduced in frequency at levels of 
uninfected controls, 2.3%  ±  0.3, but reductions were 
not seen in the 4ART-treated animals, which showed 
12.0% ± 1.6 cells (Fig. 2b). Such data supported the idea 
that the 4ART regimen stimulated cell subset production. 
A schematic chart showing CD4+ T cell frequencies in 
spleen and BM during HIV-1 and both ART regimens, as 
well as in uninfected controls, are shown in Fig. 2c.
Monocyte–macrophages and CD34+ progenitor cell 
frequencies
To determine how monocyte–macrophages and CD34+ 
progenitor cells phenotypes change during the course of 
infection and ART, we evaluated blood, spleen and BM 
cell frequencies at the study end. In monocyte–mac-
rophages, HIV-1 infection resulted in cell frequencies 
of 17.0%  ±  1.3 (in blood); 30.0%  ±  3.3 (in spleen) and 
4.9% ±  0.9 (in BM). In uninfected controls cell frequen-
cies were 11.8% ±  2.7 (in blood); 3.5% ±  0.7 (in spleen) 
and 3.0%  ±  0.5 (in BM). Differences seen during viral 
infection were altered by both ART regimens. Two and 
4ART reduced monocyte–macrophage frequencies to 
9.9% ± 2.0 and 7.8% ± 0.6 (in blood) and 3.4% ± 0.5 and 
8.5%  ±  3.1 (in spleen). The effect was not seen in BM 
from either two (4.6% ± 0.6) or 4ART (8.7% ± 1.1) during 
infection (Fig. 3). The frequencies for CD34+ progenitors 
cells from spleen were the same in all animal groups with 
0.8% ± 0.1, 0.7% ± 0.1, 0.5% ± 0.1 and 1.1% ± 0.2 seen in 
infected animals with 2 and 4ART regimens and in unin-
fected controls. Interestingly, this was not observed for 
CD34+ progenitors cells from BM, where the frequencies 
were altered by HIV-1 infection compared to uninfected 
controls of 1.8% ± 0.3 versus 0.8% ± 0.1 and in 2ART and 
4ART regimens (2.9%  ±  0.7 versus 6.1%  ±  1.6, Fig.  4). 
This result suggests that CD34+ progenitor cells turnover 
at a higher rate in BM during viral infection and ART.
Viral nucleic acids identified in T cell subsets
To determine the cellular subsets that persist in HIV-1 
infection and under antiretroviral therapy, we sorted by 
FACS and recovered several cell populations from pooled 
spleen and BM tissues of infected and treated human-
ized mice. Human CD4+ T cells were sorted for TSCM, 
TCM, TEM, and TREG subsets. Following cell recovery, viral 
nucleic acids were assayed by ddPCR for detection of 
Fig. 3 Monocyte–macrophage frequencies during HIV-1 and ART treatments. Humanized NSG mice were uninfected, infected, or infected and 
treated with 2ART or 4ART regimens. Cells from blood, spleen and BM were identified as CD3−/CD20−/CD8−/HLA-DR+/CD14+CD16+ by flow 
cytometry, as described in methods. Data were analyzed with FlowJo software. Mean ± SEM for 4–9 mice per treatment group were compared 
by one-way ANOVA, and pairwise comparisons were determined by Fisher’s LSD post hoc test. P ≤ 0.05 compared with auninfected, binfected, or 
cinfected and treated with 2ART
(See figure on previous page.) 
Fig. 2 Lymphocytes phenotypes are illustrated during HIV-1 infection and ART treatment. Humanized NSG mice were infected with HIV-1ADA, and 
after 10 weeks of infection, cellular phenotyping were detected by flow cytometry. a First, percentages of CD4+ and CD8+ T cells were determined 
from total human CD45+ CD3+ gate from blood, spleen and BM of uninfected, infected and infected and treated animal with two or four ART 
regimens. Results shown are at 10 weeks post HIV-1 infection. b Then spleen and BM CD4+ cells were investigated to determine the phenotype 
for TSCM, TCM, TEM and TREG populations in all the groups as explained in a. Cell suspensions were labelled with anti-human monoclonal antibod-
ies (mAb) targeting the following cell-surface markers: CD45, CD3, CD19, CD4, CD8, CD25, CD127, CD45RA, CD45RO, CD95, CCR7 (all from BD 
Biosciences). Data shows the percentage of the specific human CD4+ cells population. c Schematic description of the frequencies of TSCM, TCM and 
TEM and TREG during HIV-1 infection and ART treatment in humanized mice. All acquisitions were performed on a LSRII flow cytometer (Beckman 
Coulter) and data were analysed by FlowJo software. a, b Comparisons of means (±SEM) for 4–9 mice per treatment group were determined by 
one-way ANOVA and pairwise significance by Fisher’s LSD post hoc test. P ≤ 0.05 compared with auninfected, binfected, or cinfected and treated 
with 2ART
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cell-associated HIV-1. HIV-1 msRNA and usRNA as well 
as total vDNA and inDNA levels were measured in all 
human T cell subsets. Viral RNA and DNA copies from 
sorted CD4+ T cells were reduced by both ART regi-
mens (Fig. 5). Viral DNA and RNA were readily detected 
in TSCM, TCM and TEM cells following systemic infection. 
However, replicate cell types did not show significant 
msRNA, usRNA and vDNA after ART treatments. The 
ART effect was greater in the 4ART animal group; both 
in spleen or BM cells. However, inDNA was detected in 
human TSCM, TCM and TREG from spleens of mice treated 
with 4 ARVs (6 × 104, 2 × 106 and 3 × 105, respectively), 
Fig. 4 Identification of progenitor CD34+ cells. Multi-color flow cytometric analysis was performed on spleen and BM cells from humanized NSG 
mice that were uninfected, infected with HIV-1ADA or infected and treated with 2ART or 4ART regimens. Cells from each tissue were incubated with 
labeled antibodies for the identification of CD34 and Lineage-1 cellular markers. Lin-CD34+ progenitor cells were determined by the expres-
sion of CD34 marker, excluding all Lineage-1 cells. Data were analyzed with FlowJo software. Mean ± SEM of 4–9 mice per treatment group were 
compared by one way ANOVA, and pairwise comparisons were determined by Fisher’s LSD post hoc test. P ≤ 0.05 compared with auninfected, 
binfected, or cinfected and treated with 2ART
Fig. 5 Defining the levels and species of HIV-1 infection in immune CD4+ subsets from spleen and BM, without and with 2ART or 4ART. Tissues 
were collected and cells in suspension were incubated with anti-human CD45 magnetic beads for isolating human CD45+ cells previous to FACS. 
Specific antibodies were applied and TSCM, TCM, TEM, and TREG CD4+ cells were sorted. Then, sorted cells from 10 weeks HIV-1 infected humanized 
mice (4 weeks after ART) were used for detecting both viral RNA (msRNA and usRNA) and total viral DNA and inDNA as explained in methods, using 
the ddPCR system. The numbers indicate nucleic acid viral copies, RNA or DNA, per mL per each specific sorted subsets and frequencies for each 
group
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but not in BM. This suggested that infected CD4+ T cells 
from spleen remain resistant to ARV viral clearance. This 
was not seen in BM cells likely due to their high cell turn-
over that can serve to replenish virus-induced CD4+ T 
cell losses.
HIV‑1 persistence in monocyte–macrophages and CD34+ 
progenitor cells
Human monocyte–macrophages (Fig.  6) and CD34+ 
progenitor cells (Fig. 7) were immune sorted from pooled 
spleen and BM from humanized mice, then assayed for 
Fig. 6 HIV-1 infection in monocyte–macrophages from spleen and BM and intervention of ART in the frequencies on infected cells. Sorted 
monocyte–macrophages CD14+CD16+ cells were processed for RNA and DNA isolation and examined by ddPCR system as described in methods. 
Coloured dots are representations for the frequency of viral RNA or DNA of different treatment groups from spleen and BM cells. Dots in blue indicate 
the HIV-1 infected control group, dots in red are the HIV-1 infected and 2ART drug-treated group and dots in green represent HIV-1 infected and 4ART 
drug-treated group
Fig. 7 Frequency of infected progenitor CD34+ cells during HIV-1 with or without ART in humanized mice. At 10 weeks post HIV-1 infection, 
spleen and BM cells were sorted for Lin-CD34+ and were collected for RNA and DNA isolation for the detection of HIV-1 using the ddPCR system. 
Coloured dots are representations for the frequency of viral RNA or DNA of different treatment groups from spleen and BM cells. Dots in blue indicate 
HIV-1 infected control group, dots in red are for HIV-1 and 2ART and dots in green represent HIV-1 and 4ART regimens
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viral nucleic acids by ddPCR. Levels of viral usRNA and 
integrated DNA best reflect the pool of latently infected 
cells. Our results showed an unexpected pattern for 
human monocyte–macrophages from spleen, where 
viral clearance was not complete by either of ART regi-
mens and was most prevalent in the group treated with 
4 ARVs. Viral msRNA, usRNA, vDNA and inDNA cop-
ies/mL were even higher in the 4 ARV group reaching 
values of 5 × 103, 3 × 105, 8 × 105 and 9 × 104, respec-
tively. However, all viral RNA and DNAs were reduced 
to nearly undetectable levels in human monocyte–mac-
rophages from BM (101, 101, 103 and 102 copies/mL for 
viral msRNA, usRNA, vDNA and inDNA, respectively) 
(Fig.  6), which likely reflect more rapid cell turnover. 
CD34+ progenitor cells are known to be infected in 
HIV-1-infected humanized mice [40]. As shown after 
treatment with 2 or 4 ARVs, there was a significant virus 
reduction in BM cells (Fig. 7). Levels of integrated virus 
in BM cells were substantively reduced (<60 copies/mL). 
HIV-1 infected mice showed 3 × 102 viral copies/mL in 
BM cells. However, this was not observed for CD34+ 
progenitor cells from spleen and perhaps the limited cell 
recoveries precluded complete analyses of viral clearance.
Discussion
Research efforts directed at eliminating reservoirs of 
HIV-1 infection have focused on latently infected CD4+ 
T cell subsets [7, 52–55]. In addition to losses in CD4+ 
T cells along there is limitations in recruitment of virus-
specific cytotoxic T lymphocytes. Both coincide with 
the emergence of latently infected TCM [56–60]. Nota-
bly, a number of reports have shown that memory T 
cells are phenotypically altered during infection [31–35, 
61, 62]. The altered CD4+ memory and regulatory cells 
occur during HIV-1 infection are recovered by ART. Our 
results from sorted cells of spleen are in accordance with 
previous reports demonstrating that TCM cells are main-
tained during ART.
Monocyte–macrophages are an important reservoir for 
HIV infection. Such myeloid lineage cells are principal 
effectors of the innate immune system that engage multi-
ple cell and tissue functions. This includes tissue homeo-
stasis and repair to sensing and eliminating microbial 
pathogens and tumour cells (intracellular killing), secre-
tion of bioactive factors and presentation of antigen [63]. 
Macrophage infection by HIV-1 was first acknowledged 
three decades ago [48, 64] and then after multiple stud-
ies have revealed infection of tissue macrophages [5, 65, 
66] at all stages of disease, which persists under combina-
tion of ART [67]. Macrophages can promote HIV persis-
tence and tissue damage, which has been demonstrated 
in lung, the central nervous system and spleen [59, 68–
70]. In addition to producing infectious virus, spleen 
macrophages harbour latent proviral DNA and contrib-
ute as one important viral reservoir. Viral persistence in 
spleen macrophages is reflective of the cells’ long-half 
life. This affords the cells the potential to reactivate virus, 
continue to produce low level viral progeny, and be able 
to present infectious virus to T cells within the spleen 
and other lymphoid organs. Interestingly, we did not see 
this same cell behaviour for BM macrophages. Although 
the mechanism is not certain, the differences between 
these cells could reflect a faster turnover of macrophages 
in the BM, and as such make eradication much more 
difficult in these cells [71, 72]. This is based on the fact 
that monocyte turnover from bone marrow likely cor-
relates with the development of end organ disease such 
as encephalitis and pneumonitis and occurs with signs 
of global activation in plasma typified by levels of CD163 
and the actual size of the viral reservoir [73]. Certainly, 
determining how this occurs and the role different tis-
sue macrophage populations play in viral persistence will 
require additional investigation.
While the present results provide new insights into 
how we view macrophage biology in relation to tissue 
location and HIV-1 infection we accept some nota-
ble limitations in both the model and approach. First, 
macrophage phenotype and function differs amongst 
its tissue of origin and hence its microenvironment 
and may differ in tissue or origin and species (mouse 
and man) [74]. Indeed, macrophages are a highly het-
erogeneous population with phenotypic characteristics 
defined by their environment. Whether spleen or BM 
phenotypic macrophage phenotypic variability might 
affect diverse ranges of tissue-dependent suscepti-
bilities to HIV-1 infection and a spectrum of tissue 
responses that influence viral persistence, viral spread 
and pathogenic outcomes is now known [75]. Since 
the majority of studies performed on macrophages 
were based on blood-derived origins, our new findings 
likely represent specific tissue and disease specific cell 
biology made possible through this model for HIV-1 
disease. Second, the human cell grafts are themselves 
time-limited. This could influence the establishment of 
complete viral latency. Third, as the numbers of human 
cells in tissue were dependent on graft cell infiltration 
and required cell pooling to perform the viral nucleic 
acid tests, the approaches themselves imposed limi-
tations on statistical evaluations. Fourth, human cell 
reconstitution and the multiple time points evaluated 
posed limitations on the experimental design includ-
ing viral quantification of the specific cell populations. 
Nonetheless, the investigations performed herein 
would not be possible in humans. These studies taken 
together provide, for the first time, insights into the 
role of subpopulations of human immune cells serve as 
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viral reservoirs under combination long-acting ART in 
humanized mice.
The phenotypic changes of several immune cells 
affected during HIV-1 infection were previously found 
[40]. However, ART-affected phenotypic changes were 
seen in the present report and as such we were now able 
to determine populations of immune cells that enable per-
sistent viral infection. Such cell populations are linked to 
on-going infection and viral spread in a spectrum of tis-
sues. Indeed, differences seen between two and four ARVs 
also provide unique insights into the effectiveness of spe-
cific therapies. Even considering that ¼ of animals showed 
HIV-1 in plasma when receiving 4ART the treatment 
could serve to ultimately clear virus. This would occur 
in this animal if the time point was longer plus the dilu-
tion factor and estimated calculation required for plasma 
viral load analysis (copies/mL) was adjusted. Together, our 
findings show an important role of both memory CD4+ 
T cells and macrophage infection, specifically in spleen 
or BM. We posit that these long-live memory CD4+ T 
cells contribute to viral persistence. Macrophages capture 
and uptake infected CD4+ T cells and become infected 
and remains as reservoirs even under suppressive ART, 
as shown in our results by demonstrating the presence 
of integrated viral DNA in spleen macrophages, which 
can be a consequence of the ingestion of latently infected 
memory CD4+ T cells which also persist with any of both 
ART regimens. These particular events seems to be criti-
cal in spleen tissue, contrary to BM niche where there is 
a significant reduction of HIV-1-infected memory and 
regulatory CD4+ T cells, macrophages and progenitor 
hematopoietic cells. Cellular turnovers may dictate the 
capacity for viral infection and persistence, and differ-
ences in turnovers in peripheral blood, spleen and BM 
cells can definitely play a major role during HIV-1 infec-
tion during antiretroviral treatment.
To note, both ART regimens, used in this study, did 
not accomplished the capacity to clear infected cen-
tral memory CD4+ T cells neither macrophages from 
pooled spleen tissue in our single experiment; perhaps 
differences could be noted by analysing single individuals 
rather than as a total group but we face the limitation of 
human cells recovery in this animal model. These reser-
voirs of infected cells will have the capacity to establish 
the infection and to carry integrated viruses that may 
contribute to disease progression. We posit that in dif-
ferentiated tissue macrophages mature virions actively 
assemble and accumulate in invaginations of the plasma 
membrane becoming a virus-containing compartment 
that include late endosomes [76, 77]. Such virus-con-
taining compartments cannot be reached by our ARVs 
thus begging the question of the native drug failures. Our 
group is currently focusing on the development of such 
long-acting ARVs and to target the same cellular com-
partments as virus [78] therefore facilitating improved 
treatments for viral clearance.
Results uncovered in this study that were not initially 
anticipated. One rested in the similar percentage of cell 
subsets seen between uninfected “control” mice and 
2ART-treated mice, but not in 4ART-treated mice. Con-
trol and 2ART-treated infected mice had similar percent-
ages of splenic and bone marrow memory and regulatory 
CD4+ T cells, but not early memory progenitors of 
CD4+ T and bone marrow Tscm cells. This suggested 
that the 4ART combination regimen induced cellular 
proliferation or high turnover of specific bone marrow 
populations. In support of this idea, spleen and bone 
marrow showed divergent behaviors. This paralleled our 
previously published data in humanized mice and was 
also found to be true for infected people when lympho-
cyte turn-over rates were evaluated after initiation of 
antiretroviral therapy [40]. Second, in a study using deu-
terated glucose to label DNA of proliferating cells, T cell 
dynamics in normal subjects and HIV-1-infected patients 
that were naive to antiretroviral drugs also showed diver-
gent results amongst patients. Here rates of lymphocyte 
proliferation influence CD4+ T cell death [79]. Notably, 
CD8+ T cells proliferation rates are higher in infected 
people without mean death rates being influenced. Third, 
a parallel study that examined immune consequences 
following antiretroviral therapy demonstrated lympho-
cyte proliferation and death rates in CD4+ and CD8+ cell 
populations were linked to time, antiretroviral drug regi-
men, cell activation, end organ drug levels, gender, tis-
sue type, and level of viral infection [80, 81]. Fourth, the 
largest decline was associated with effector memory and 
regulatory CD4+ T cells. Such changes were observed 
in all tested compartments. Fifth, the presence of stem 
cells in bone marrow and their relative expansion dur-
ing infection and treatment could be affected by the types 
of ART and by differential responses seen by naïve cells. 
Thus, there are a number of potential explanations for 
why the 2ART and 4ART regimens behaved differently 
in these studies. Definitive tests are planned on human 
cells recovered from populations of murine bone mar-
row to test mechanisms of drug action, and as such, cell 
populations in divergent tissues are currently being re-
evaluated. The second centered on the different impacts 
seen by ART in blood and spleen versus bone marrow. 
We posit that this could be explained by myelopoie-
sis which results in the constant generation of human 
monocytes. This process occurs only in bone morrow, 
but not in peripheral blood, and only at very limited lev-
els in spleen. In this way expansion of macrophages that 
occurs during HIV-1 infection could be dependent on 
cell turnover rates. To this end, we now report changes 
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in macrophage frequency of infection with and without 
ART. These findings paralleled a prior report that showed 
reductions in CD4+ T cell generation in bone marrow 
CD34+ progenitors during simian immunodeficiency 
virus infected macaques that resulted from changes in 
the clonogenic potential of marrow progenitors, which 
were of both myeloid and lymphoid lineage [82]. Hemat-
opoietic failure was reported early in infection and in the 
absence of CD34+ infection and not linked to plasma 
viral load. Failure of hematopoiesis impairs T cell pro-
duction in the bone marrow compartment, and as such, 
likely reflects tissue divergence. In the current study, 
our infected humanized mice showed higher frequen-
cies of CD34+ cells during HIV-1 infection compared 
to uninfected control animals. Cellular frequencies were 
found affected by 2ART or 4ART treatment regimens. 
However, bone marrow cells did not respond the same 
as spleen cells as higher cell frequencies were observed 
during infection that did not return to a level observed 
in controls (uninfected, untreated animals). This sug-
gested that once bone marrow is stimulated by infection, 
it results in higher cell frequencies. As virus populations 
in plasma and tissues differ significantly between treated 
and untreated infected animals suggests the exchange 
of virus or infected cells between tissue compartments. 
Thus, the differences are more likely reflective of cell type 
rather than differences in virus as viral replication during 
highly suppressive ART is limited [83]. Taken together, 
the ability of virus to stimulate cellular proliferation and 
perhaps cell turnover from bone marrow likely impacted 
different ART effects in blood, spleen, and bone marrow.
Conclusion
We identified cellular reservoirs sites that persist after 
HIV-1 infection despite antiretroviral drug therapy 
(ART) in humanized mice. This study defines the HIV-1 
cellular network in humanized mice and a potential cell 
source for viral persistence. The work serves as a model 
for future investigations to design antiretroviral therapies 
that target and ultimately clear cellular viral reservoirs.
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